Literature DB >> 9461057

Bilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects.

E M Sigurdsson1, J M Lee, X W Dong, M J Hejna, S A Lorens.   

Abstract

To examine the time course of the histopathological effects of bilateral injections of amyloid-beta 25-35 (A beta) and to determine if these effects are associated with a reduction in choline acetyltransferase activity and behavioral impairments, we injected A beta (5.0 nmol) into the amygdala of young male Fischer rats. Control rats received vehicle infusions. For histological analysis, animals were sacrificed at 8, 32, 64, 96, and 128 days postoperatively (n = 21-33 per timepoint). A beta induced neuronal tau-2 staining in the right, but not the left amygdala and hippocampus. A beta also induced reactive astrocytosis and neuronal shrinkage within the right hippocampus and amygdala, respectively. As with tau-2, these same brain regions within the left hemisphere in the A beta-treated rats were significantly less affected. In addition, A beta appeared to induce microglial and neuronal interleukin-1beta staining. The histopathological effects of A beta peaked at 32 days postoperatively but were not associated with a reduction in amygdaloid choline acetyltransferase activity. In a separate experiment, behavioral effects of bilateral intra-amygdaloid injections of A beta were analyzed at 34-52 days postoperatively. In an open field test, the treatment groups differed only in the numbers of rears emitted (p = 0.016). There was no effect of A beta in the Morris water maze or in the acquisition and retention of a one-way conditioned avoidance response. These data suggest a laterality in the histopathological effects of A beta and that the effects of single injections are in part transient. These findings also suggest a direct association between plaque and tangle formation in Alzheimer's disease, and support the use of this rat model to screen drugs that may alter the initial pathological events associated with Alzheimer's disease, that occur before the manifestations of extensive behavioral impairments become evident.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9461057     DOI: 10.1016/s0197-4580(97)00154-1

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  20 in total

1.  Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.

Authors:  Sarah L DeVos; Bianca T Corjuc; Caitlin Commins; Simon Dujardin; Riley N Bannon; Diana Corjuc; Benjamin D Moore; Rachel E Bennett; Mehdi Jorfi; Jose A Gonzales; Patrick M Dooley; Allyson D Roe; Rose Pitstick; Daniel Irimia; Matthew P Frosch; George A Carlson; Bradley T Hyman
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

2.  Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.

Authors:  Jiaping Gu; Erin E Congdon; Einar M Sigurdsson
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

Review 3.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

Review 4.  Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

Review 5.  Immunotherapy for tauopathies.

Authors:  Jiaping Gu; Einar M Sigurdsson
Journal:  J Mol Neurosci       Date:  2011-07-08       Impact factor: 3.444

6.  Neuroprotective Role of Novel Triazine Derivatives by Activating Wnt/β Catenin Signaling Pathway in Rodent Models of Alzheimer's Disease.

Authors:  Anshuman Sinha; Riyaj S Tamboli; Brashket Seth; Ashish M Kanhed; Shashi Kant Tiwari; Swati Agarwal; Saumya Nair; Rajani Giridhar; Rajnish Kumar Chaturvedi; Mange Ram Yadav
Journal:  Mol Neurobiol       Date:  2014-09-26       Impact factor: 5.590

Review 7.  Immunization treatment approaches in Alzheimer's and prion diseases.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 8.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

9.  Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.

Authors:  Suhail Rasool; Hilda Martinez-Coria; Jessica W Wu; Frank LaFerla; Charles G Glabe
Journal:  J Neurochem       Date:  2013-06-16       Impact factor: 5.372

10.  Nonhuman amyloid oligomer epitope reduces Alzheimer's-like neuropathology in 3xTg-AD transgenic mice.

Authors:  Suhail Rasool; Hilda Martinez-Coria; Saskia Milton; Charles G Glabe
Journal:  Mol Neurobiol       Date:  2013-06-15       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.